Replies to post #1428 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Model assumptions: 30% G/P market share; pricing similar to Harvoni and Viekira (net of discounts and rebates).

Note that ENTA gets a 67% higher royalty per dollar of G/P sales than they do per dollar of Viekira sales.